The DOI matches its Crossref record; 78 of the 81 references it cites were found in a registry or an index.
JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
Published version of a preprint
Abstract
Purpose: Recent advances have seen the development of targeted therapeutics against the receptor tyrosine kinase (RTK)/RAS/MAPK pathway, which, when aberrantly activated, drives the malignant transformation of many cancer indications. However, the efficacy of inhibitors targeting single molecules is dampened by pathway feedback activation and acquired drug resistance. We seek to evaluate the application of JAB-3312 (sitneprotafib), a potent inhibitor of SHP2, in RTK/RAS/MAPK pathway–targeted combination therapies. Furthermore, SHP2 plays a vital role in PD-1–mediated immunosuppression. The rational combination of JAB-3312 with PD-1 blocking therapies is also explored. Experimental Design: Biochemical and cellular assays were applied to evaluate the potency of JAB-3312 in SHP2 inhibition. Tumor cell lines and cell line– and patient-derived xenografts were used to test different combinations of JAB-3312 with KRASG12C, MEK, EGFR, and PD-1 inhibitors. Results: JAB-3312 produced potent in vitro inhibition of SHP2 activity and downstream ERK phosphorylation, with IC50 values of 1.44 nmol/L and 0.68 to 4.84 nmol/L, respectively. When used in combination, JAB-3312 significantly increased the antitumor activity of the KRASG12C inhibitor glecirasib in naïve and resistant models. The combination of JAB-3312 with MEK inhibitors significantly delayed RTK signaling reactivation and enhanced tumor growth inhibition in KRAS-mutated cancer models. The JAB-3312–osimertinib combination exhibited great efficacy in osimertinib-resistant non–small cell lung cancer models. Additionally, JAB-3312 enhanced the efficacy of PD-1 blockade therapies by promoting an antitumor microenvironment. Representative cases of patients who responded to the combination therapies from two ongoing clinical trials (NCT05288205 and NCT04720976) were reported. Conclusions: JAB-3312 in combination with RTK/RAS/MAPK or PD-1 blockade therapies is a promising strategy that warrants further clinical investigation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024) · CA: a cancer journal for clinicians · doi:10.3322/caac.21834 · Cited by 27,064
Cancer incidence and mortality in China, 2022
Han, B., Zheng, R., Zeng, H., Wang, S., Sun, K., Chen, R., Li, L., Wei, W., & He, J. (2024) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2024.01.006 · Cited by 2,243
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Leonetti, A., Sharma, S., Minari, R., Perego, P., Giovannetti, E., & Tiseo, M. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0573-8 · Cited by 1,409
KRAS Mutation: From Undruggable to Druggable in Cancer
Huang, L., Guo, Z., Wang, F., & Fu, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00780-4 · Cited by 1,127
Mechanisms of receptor tyrosine kinase activation in cancer
Du, Z., & Lovly, C. M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0782-4 · Cited by 1,066
The quest to overcome resistance to EGFR-targeted therapies in cancer
Chong, C. R., & Jänne, P. A. (2013) · Nature Medicine · doi:10.1038/nm.3388 · Cited by 1,052
Crystal Structure of the Tyrosine Phosphatase SHP-2
Hof, P., Pluskey, S., Dhe-Paganon, S., Eck, M. J., & Shoelson, S. E. (1998) · Cell · doi:10.1016/s0092-8674(00)80938-1 · Cited by 985
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Chen, Y.-N. P., LaMarche, M. J., Chan, H. M., Fekkes, P., Garcia-Fortanet, J., Acker, M. G., Antonakos, B., Chen, C. H.-T., Chen, Z., Cooke, V. G., et al. (2016) · Nature · doi:10.1038/nature18621 · Cited by 925
Self-citationTargeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Bahar, M. E., Kim, H. J., & Kim, D. R. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01705-z · Cited by 888
Research works printed but not linked: 2
- FDA, 2018, Multi-disciplinary review and evaluation NDA 210498
- Surveillance, Epidemiology and End Results Program (SEER), Cancer stat facts: cancer any site
Cited by
Zhong, J., Zhao, J., Duan, J., Fang, J., Fei, K., Li, X., Chen, J., Wang, Z., Chu, Q., Yu, Y., et al. (2025) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(25)00258-9 · Cited by 19
Self-citationInsights into RAS-driven melanoma and its therapeutic implications
Chatziioannou, E., Lallas, K., Sinnberg, T. W., Niessner, H., Stratigos, A., Flatz, L., & Amaral, T. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103090 · Cited by 7
The evolving landscape of KRAS-targeted therapy: mechanisms of resistance and emerging strategies
Pilco‐Janeta, D. F., & Puebla, M. D. L. C. (2025) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001801 · Cited by 2
Chen, Z., Wang, M.-L., Zhang, Z.-W., Zhang, P.-C., Yang, Q.-F., Weng, Y., Shen, J.-L., Wang, W., & Shao, L. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102972 · Cited by 2
“This therapeutic strategy has demonstrated potential in enhancing the survival rates of patients with advanced NSCLC [4].”
Pereira, R. A., Oliveira, C., Tumelero, M., Fernandes, H., & Lenz, G. (2026) · Oncology Research and Treatment · doi:10.1159/000550885
“By blocking this feedback loop, SHP2 inhibitors like JAB-3312 and TNO155 can increase the efficacy of KRAS-targeted treatment [59–61].”
Metadata
- Authors
- Kang, D., Wang, Y., Lin, Y., Ma, W. W., Morgensztern, D., Leventakos, K., Bi, C., Ding, Y., Xiong, J., Yan, M., Sun, X., Wang, P., Ma, C., & Wang, Y.
- Affiliations
- 1Department of Pharmacology, Jacobio Pharmaceuticals Co., Ltd., Beijing, China.
- 2Department of Translational Medicine, Jacobio (US) Pharmaceuticals, Inc., Burlington, Massachusetts.
- Cleveland Clinic (US)
- Washington University in St. Louis (US)
- Mayo Clinic (US)
- 6Department of Clinical Medicine, Jacobio Pharmaceuticals Co., Ltd., Beijing, China.
- 7Department of Translational Medicine, Jacobio Pharmaceuticals Co., Ltd., Beijing, China.
- 8Department of Medicinal Chemistry, Jacobio Pharmaceuticals Co., Ltd., Beijing, China.
- 9Jacobio Pharmaceuticals Group Co., Ltd., Beijing, China.
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2025-05-07
- Volume
- 31
- Issue
- 14
- Pages
- 3019-3032
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W4410156573
- Cited by
- 17
- References
- 81
- Citations by year
- 2026: 15 · 2025: 2
- FWCI
- 5.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- SHP2 inhibitors, allosteric inhibition, KRAS G12C, MEK inhibitors, EGFR inhibitors, anti-PD-1 therapy, combination therapy, acquired drug resistance, ERK1/2 phosphorylation, osimertinib resistance, non-small cell lung cancer
- MeSH terms
- Animals, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Signal Transduction, ras Proteins, Receptor Protein-Tyrosine Kinases, MAP Kinase Signaling System, Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, Mice, Protein Tyrosine Phosphatase, Non-Receptor Type 11, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-24-3691
- The paper
- Kang, D., Wang, Y., Lin, Y., Ma, W. W., Morgensztern, D., Leventakos, K., Bi, C., Ding, Y., Xiong, J., Yan, M., Sun, X., Wang, P., Ma, C., & Wang, Y. (2025). JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-24-3691
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.